AEGiS-11IAC: Immunologic and virologic evaluation of influenza vaccination of HIV-1-infected patients.

11th International AIDS Conference

Vancouver, British Columbia — July 7-12, 1996

Immunologic and virologic evaluation of influenza vaccination of HIV-1-infected patients.

Int Conf AIDS 1996 Jul 7-12; 11:226 (abstract no. Tu.A.385)
Fowke KR, D'Aimicom R, Chernoff DN, Pottage J, Bensen C, Sha B, Kessler HA, Landay AL, Shearer GM; National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. Fax: (301)402-3643.

OBJECTIVE: Evaluation of the effects of influenza vaccination of HIV-1-infected patients on HIV associated immunologic and virologic parameters.

METHODS: Forty-six persons (36 HIV-infected, 10 uninfected controls) were given influenza vaccine while on stable combination therapy. Blood was collected at the time of vaccination (week 0) and at visits 2, 4, and 12 weeks post vaccination. Immunologic evaluation included: three color flow cytometry of activation (CD38, HLA-DR, CD25, CD71) and maturation (CD45Ra, CD62L) markers on CD4 and CD8 subsets; detection of peripheral blood mononuclear cell spontaneous, mitogen and antigen stimulated apoptotic cell death by microscopic evaluation of nuclear morphology; T helper cell functional analysis by IL-2 production and proliferation; and influenza antibody titre. Quantitative plasma HIV-1 RNA was determined by bDNA.

RESULTS: Fourteen individuals (12 HIV-infected, 2 controls) have been analyzed through week 4 post vaccination. Mean CD4 counts at enrollment (HIV+, 184.9 plus or minus 187.0; HIV-, 943.0 plus or minus 156.9) did not significantly change during the initial four weeks. Flow cytometric analysis indicated no change in the relative percentages of cellular phenotypes nor their activation or memory states. Spontaneous, mitogen and antigen induced apoptotic cell death was higher in the HIV-infected group, compared to controls, but neither group showed a change over the first four weeks of the study. Plasma HIV RNA was assessed in 28 of the HIV-infected group at 0, 2 and 4 weeks post immunization. While there were no changes in twenty (71.4%) of the participants at week 4, 4 (14.3%) showed a greater than 0.5 log increase and 4 (14.3%) a greater than 0.5 log decrease in viral burden.

CONCLUSIONS: Immunization of HIV-infected patients with influenza vaccine did not result in alterations in any of the immunologic parameters evaluated. The effects of influenza vaccination on apoptotic cell death in HIV-infected people with higher CD4 counts are being further evaluated. Influenza immunization did not result in predictable increases in plasma HIV RNA which may have been due to continued anti-viral therapy during the study.

Keywords: AEGIS, HIV-1, CD4 Lymphocyte Count, HIV, Viral Load, HIV Infections, Influenza Vaccine, Anti-HIV Agents, Vaccination, Antibodies, Viral, Evaluation Studies, Influenza, T-Lymphocytes, Helper-Inducer, Influenza B virus, Influenza A Virus, Human, Human, virology, immunology, ICA11

960707
TuA385